TREM2 Deficiency Reprograms Intestinal Macrophages and Microbiota to Enhance Anti–PD-1 Tumor Immunotherapy

TREM2 Deficiency Remodels Intestinal Macrophages and Microbiota to Enhance Anti-PD-1 Tumor Immunotherapy A research team from the Washington University School of Medicine, led by Blanda Di Luccia and other scientists, recently published a study in the journal Science Immunology, revealing how intestinal microbiota and tumor-associated macrophages i...

The Effect of B7H6 Ligand on T Cell Responses

Immunoglobulin Superfamily Ligand B7H6 Enables T Cell Responses under NK Cell Surveillance Background In the field of immunology, understanding the mechanisms regulating T cell immunity is crucial for developing effective therapies for diseases related to T cell dysfunction, such as autoimmune diseases, chronic infections, and cancer. T cells media...

LRIG1 engages ligand VISTA and impairs tumor-specific CD8+ T cell responses

Immunotherapy Checkpoint Inhibitors (ICIs, also known as immune checkpoint blockers) are a class of drugs that have achieved significant breakthroughs in cancer immunotherapy in recent years. These drugs mainly work by blocking Programmed Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4), thereby activating anti-tumor ...

Targeted depletion of PD-1–expressing cells induces immune tolerance through peripheral clonal deletion

Inducing Immune Tolerance through Peripheral Clonal Deletion Targeting PD-1 Expressing Cells Background Introduction The establishment of T-cell receptor (TCR) repertoire through thymic negative selection is a key process for achieving self-tolerance and acquired tolerance post-organ transplantation. However, it remains unclear whether the specific...

The Tumor-Intrinsic Role of the m6A Reader YTHDF2 in Regulating Immune Evasion

Report: Intrinsic Role of m6A Reader Protein YTHDF2 in Regulating Tumor Immune Evasion Background Introduction In recent years, immunotherapy has become a hotspot in the field of tumor treatment, attracting attention for its ability to break through immune suppression barriers or enhance existing anti-tumor immunity. However, despite some successes...

Intratumoral Antigen Signaling Traps CD8+ T Cells to Confine Exhaustion to the Tumor Site

Tumor Immunology Research: The Exhausted State of CD8+ T Cells in Tumors In recent years, immunotherapy has achieved significant progress in the field of tumor treatment. However, tracking the behavior of lymphocytes following antigen signals remains challenging. This study aims to address this issue by developing Antigen Receptor Signaling Reporte...